Minocycline Hydrochloride

Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk The demand is strong: 96% of surgeons surveyed are interested in adopting NXT-41x; 92% responded they would champion it at their hospital value analysis committee On track: NXT-41 FDA clearance decision expected in 4Q 2026; NXT-41x FDA clearance decision expected in 1H 2027 GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and announced financial results for the second quarter ended June 30, 2026. “We have intentionally focused Elutia where our strengths create the greatest value for patients and shareholders,” said Dr. Randy Mills, Chief Executive Officer of Elutia. “We believe we are now funded through the anticipated clearance and full commercial launch of NXT-41x, our antibiotic-eluting biomatrix for use in plastic and reconstructive surgical procedures. And we did it without an equity offering. “As we approach anticipated FDA clearance decisions and launch, surgeon interest in NXT-41x has exceeded our expectations. In an independent study of 50 board-certified plastic and reconstructive surgeons, 86% said matrices used today increase infection risk, 96% believed our antibiotic combination would be effective at preventing infection, and 92% said they would help get NXT-41x approved at their hospital’s value analysis committee. “Having successfully created value with this technology in the pacemaker market, we are now applying it to a larger market with a substantially greater unmet need. And we believe we have the team and capital to execute.” Capital Secured to Support NXT-41x Through Clearance and Commercial Launch Elutia has secured up to $26 million of additional capital to support the Company through the anticipated clearance of NXT-41x and its first full year of commercial launch in 2028, without an equity offering: $15 million credit facility, including $10 million funded at closing and an additional $5 million available following NXT-41x FDA clearance Up to $11 million from the SimpliDerm divestiture, including $8 million in cash at closing and up to $3 million in contingent technology transfer and commercial milestone payments In addition, the Company anticipates receiving the full $8 million held in escrow from the 2025 divestiture of the BioEnvelope business, with release expected in the fourth quarter of this year. Independent Blinded Survey Validates Surgeon Demand for NXT-41x An independent market research firm conducted a blinded survey of 50 board-certified plastic and reconstructive surgeons across 28 states. The surgeons average 11.6 years in practice and perform about 140 complex reconstructive procedures annually. Surgeons Say the Problem Is Real Surgeons estimate a 17% surgical-site infection rate in the published literature for these procedures. 86% (95% confidence interval (CI): 74–93%) report that matrices used today increase infection risk. Surgeons View NXT-41x as Differentiated and Mechanistically Sound 98% (CI: 90–99.6%) rated NXT-41x new and different from products available today. 96% (CI: 87–99%) rated the combination of rifampin and minocycline effective, with 64% (CI: 50–76%) describing it as extremely effective at reducing surgical site infections. No respondents rated the combination ineffective. Surgeon Intent to Adopt NXT-41x Is Strong 100% (CI: 93–100%) indicated they would use NXT-41x in diabetic patients and in patients with high BMI, who together represent approximately one third of all reconstruction patients. 96% (CI: 87–99%) expressed interest in incorporating NXT-41x into their general practice. 92% (CI: 81–97%) indicated willingness to approach their hospital value analysis committee in support of NXT-41x. Interest measures are based on ratings of 4 or 5 on a five-point scale. All results are reported with 95% Wilson confidence intervals; where responses were unanimous, the lower bound of the interval is 93%. Regulatory Review and Manufacturing Progressing on Schedule Regulatory and development activities for both NXT-41 (biologic surgical matrix without drug) and NXT-41x continue to advance according to plan. Elutia recently held a productive meeting with the FDA regarding the NXT-41 submission, which remains on track. The Company continues to expect FDA clearance for NXT-41 in the fourth quarter of 2026 and for NXT-41x in the first half of 2027. Elutia also completed the installation and operational qualification of its automated drug-coating system for commercial manufacturing. The system is designed to support target gross margins in excess of 80% at scale. Product Divestitures Further Sharpen the Company’s Focus On July 16, 2026, Elutia signed a definitive agreement to sell its SimpliDerm business for up to $11 million in total consideration, including up to $3 million in contingent technology transfer and commercial milestone payments over the 18 months following closing, with closing expected in the third quarter of 2026. The Company’s previously announced strategic process for its Cardiovascular business also continues to advance. Together with the 2025 divestiture of the BioEnvelope business, these transactions extend Elutia’s runway and focus the organization on the launch of NXT-41x in the second half of 2027. Funded Catalysts Ahead Milestone Expected Timing SimpliDerm business divestiture closing 3Q 2026 Potential cardiovascular business transaction 2H 2026 $8 million BioEnvelope escrow release 4Q 2026 NXT-41 FDA clearance decision 4Q 2026 NXT-41x FDA clearance decision 1H 2027 NXT-41x commercial soft launch 2H 2027 NXT-41x full commercial launch 2028 Second Quarter 2026 Financial Results Net sales and operating results discussed below reflect continuing operations. For the three-month period ended June 30, 2026, as compared to the same period of 2025: Overall net sales were $2.4 million, compared to $2.7 million. The decrease was the result of $0.7 million reduction in SimpliDerm revenue due to a production disruption with the product’s contract manufacturer, offset by a $0.4 million increase in Cardiovascular revenue due to the transition back to direct sales. Gross margin on a GAAP basis was 59.6%, compared to 52.9%. Adjusted gross margin (a non-GAAP measure which excludes non-cash amortization of intangibles) was 70.7%, compared to 62.7%. A reconciliation of GAAP gross margin to adjusted gross margin is included in the accompanying financial tables. Total operating expenses were $9.4 million, compared to $9.8 million. The decrease was driven by a $1.9 million reduction in net litigation costs, partially offset by a $1.5 million increase in research and development expense supporting the NXT-41 and NXT-41x programs. Loss from operations was $8.0 million, compared to $8.4 million. Net loss from continuing operations was $7.6 million, compared to $7.1 million. There was no loss from discontinued operations in the second quarter of 2026, compared to a loss of $2.5 million in the second quarter of 2025. Net loss was $7.6 million, compared to $9.6 million. Adjusted EBITDA (a non-GAAP measure that excludes from net loss certain non-operating, non-cash and non-recurring items) was a loss of $4.6 million, compared to a loss of $3.0 million. A reconciliation of net loss to adjusted EBITDA is included in the accompanying financial tables. Cash and cash equivalents at June 30, 2026 were $19.9 million. This cash position is expected to be augmented by up to an additional $34 million from signed transactions, including $10 million already received from Avenue Capital Group pursuant to a new loan agreement, $8 million held in escrow in connection with the 2025 divestiture of the BioEnvelope business, up to $11 million from the sale of the SimpliDerm business and an additional $5 million available from the Avenue Capital loan facility following FDA clearance of NXT-41x. Conference Call Elutia will host a conference call on August 13, 2026 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to discuss its second quarter 2026 financial results and business performance. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register. Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the "Investors" section of the Elutia website at About Elutia Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit Non-GAAP Disclosure In addition to the Company’s financial results determined in accordance with U.S. GAAP, the Company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The Company presents in this press release the following non-GAAP financial measures: earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted earnings before interest, taxes, depreciation and amortization ("adjusted EBITDA"), adjusted gross margin and adjusted gross profit. The Company defines EBITDA as GAAP net loss excluding interest expense, income tax expense, depreciation and amortization, and the Company defines adjusted EBITDA as EBITDA excluding income or loss from discontinued operations, stock-based compensation, FiberCel and VBM litigation costs, loss or gain on revaluation of warrant liability, warrant issuance expenses and loss or gain on revaluation of revenue interest obligation. The Company defines adjusted gross profit and adjusted gross margin as GAAP gross profit and GAAP gross margin, respectively, excluding amortization of acquired intangible assets. The amortization of these intangible assets will recur in future periods until such intangible assets have been fully amortized. Management believes that presentation of non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. The Company uses this non-GAAP financial information to establish budgets, manage the Company’s business, and set incentive and compensation arrangements. Non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental information purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. For a reconciliation of these non-GAAP measures to GAAP, see below "Non-GAAP Reconciliations of EBITDA and Adjusted EBITDA" and "Non-GAAP Reconciliations of Adjusted Gross Profit and Adjusted Gross Margin." Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including any statements and information concerning our future interactions with the U.S. Food and Drug Administration ("FDA") regarding NXT-41 and NXT-41x; expectations for FDA clearance of NXT-41 and NXT-41x, including the timing and anticipated success thereof; preparations for the commercial launch of NXT-41x, including the timing, scale and anticipated success thereof; the sufficiency of our capital resources to fund the Company through anticipated FDA clearance and the first full year of commercial launch of NXT-41x without an equity offering; the availability of the additional $5 million tranche under our Avenue Capital financing; the expected closing of the sale of our SimpliDerm business and our receipt of the associated contingent technology transfer and commercial milestone payments; the outcome and timing of the previously announced strategic process for our Cardiovascular business; the anticipated release of the $8 million held in escrow in connection with the divestiture of the BioEnvelope business; the results, interpretation and predictive value of the independent blinded surgeon survey described in this press release, including surgeons’ stated intent to adopt NXT-41x and to support it before hospital value analysis committees; the size of the plastic and reconstructive surgery market and the potential of the Company’s next-generation drug-eluting biomatrix pipeline to compete in that market; expectations regarding manufacturing capacity, scale and target gross margins; and any statements regarding future liability with respect to the FiberCel and VBM litigation. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings, including NXT-41 and NXT-41x; our ability to obtain regulatory approval or other marketing authorizations by the U.S. Food and Drug Administration and comparable foreign authorities for our products and product candidates, including NXT-41 and NXT-41x; our ability to comply with the covenants under, and to draw the remaining availability under, our credit facility; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to achieve or sustain profitability; our ability to regain compliance with Nasdaq’s minimum bid price requirement and otherwise maintain compliance with any other listing requirement of Nasdaq Capital Market, and our ability to maintain a listing of our Class A common stock on the Nasdaq Capital Market; our ability to raise funds in the future in the amounts and at the times needed; our ability to service our indebtedness; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; risks relating to the pending sale of the SimpliDerm business, including the occurrence of any event, change or circumstance that could delay the sale of the SimpliDerm business or give rise to termination of the related asset purchase agreement, the risk that the technology transfer and commercial milestone payments from the sale of the SimpliDerm business are reduced, delayed, or not earned or received, the outcome of any legal proceedings instituted against us following announcement of the sale of the SimpliDerm business, the inability to consummate the sale of the SimpliDerm business due to failure to satisfy closing conditions; the risk that the sale of the SimpliDerm business disrupts our current plans and operations, including distraction of management and employees, and costs related to the sale of the SimpliDerm business; our ability to complete any strategic transaction involving our Cardiovascular business, on the anticipated timeline and terms, or at all, and to realize the anticipated benefits of that transaction; our ability to defend against the various lawsuits and claims related to our former FiberCel and other bone viable matrix (“VBM”) products and avoid a material adverse financial consequence; the continued and future acceptance of our products by the medical community; our dependence on independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations could adversely affect our sales and profitability; our ability to obtain, maintain and adequately protect our intellectual property rights; and other important factors which can be found in the "Risk Factors" section of Elutia’s public filings with the Securities and Exchange Commission ("SEC"), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in Elutia’s other filings with the SEC, including Elutia’s Quarterly Reports on Form 10-Q, accessible on the SEC’s website at and the Investor Relations page of Elutia’s website at Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investors: Elutia Investor Relations ir@elutia.com ELUTIA INC. CONSOLIDATED BALANCE SHEET DATA (Unaudited, in thousands) Assets June 30, 2026 December 31, 2025 Current assets: Cash and cash equivalents $ 19,896 $ 36,350 Accounts receivable, net 1,438 1,734 Inventory 2,649 2,617 Insurance receivables of litigation costs 3,854 4,846 Prepaid expense and other current assets 9,378 10,271 Total current assets 37,215 55,818 Property and equipment, net 2,922 2,511 Intangible assets, net 990 1,529 Operating lease right-of-use assets, and other 2,522 2,492 Total assets $ 43,649 $ 62,350 Liabilities and Stockholders' Equity Current liabilities: Accounts payable and accrued expenses $ 8,329 $ 9,143 Current portion of revenue interest obligation 6,412 4,400 Contingent liability for legal proceedings 5,619 11,241 Current operating lease liabilities 685 355 Total current liabilities 21,045 25,139 Long-term revenue interest obligation — 2,828 Warrant liability 3,163 3,124 Long-term operating lease liabilities 3,695 3,587 Total liabilities 27,903 34,678 Stockholders' equity: Common stock 44 43 Additional paid-in capital 207,030 203,842 Accumulated deficit (191,328 ) (176,213 ) Total stockholders' equity 15,746 27,672 Total liabilities and stockholders' equity $ 43,649 $ 62,350 ELUTIA INC. CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited, in thousands, except share and per share data) Three months ended June 30, Six months ended June 30, 2026 2025 2026 2025 Net sales $ 2,427 $ 2,747 $ 5,541 $ 5,698 Cost of goods sold 980 1,294 2,292 2,863 Gross profit 1,447 1,453 3,249 2,835 Operating expenses: Sales and marketing 1,366 1,273 2,846 2,268 General and administrative 3,454 3,552 7,545 7,273 Research and development 2,527 989 4,500 1,860 Litigation costs, net 2,057 4,004 2,663 6,576 Total operating expenses 9,404 9,818 17,554 17,977 Loss from operations (7,957 ) (8,365 ) (14,305 ) (15,142 ) Interest income, net (35 ) (491 ) (143 ) (307 ) Other (income) expense, net (284 ) (791 ) 1,300 (5,873 ) Loss before provision for income taxes (7,638 ) (7,083 ) (15,462 ) (8,962 ) Provision for income taxes 8 8 78 16 Net loss from continuing operations (7,646 ) (7,091 ) (15,540 ) (8,978 ) Loss income from discontinued operations — (2,519 ) 425 (4,565 ) Net loss $ (7,646 ) $ (9,610 ) $ (15,115 ) $ (13,543 ) Net loss per share — basic $ (0.17 ) $ (0.23 ) $ (0.35 ) $ (0.34 ) Net loss per share — diluted $ (0.17 ) $ (0.26 ) $ (0.35 ) $ (0.47 ) Weighted average common shares outstanding — basic 44,223,722 41,782,556 43,622,360 40,239,372 Weighted average common shares outstanding — diluted 44,223,722 46,308,642 43,622,360 44,765,897 ELUTIA INC. NON-GAAP GROSS PROFIT AND NON-GAAP GROSS MARGIN RECONCILIATIONS (Unaudited, in thousands) Three months ended June 30, Six months ended June 30, 2026 2025 2026 2025 Net sales $ 2,427 $ 2,747 $ 5,541 $ 5,698 Gross profit 1,447 1,453 3,249 2,835 Intangible asset amortization expense 270 270 540 542 Adjusted gross profit (Non-GAAP) $ 1,717 $ 1,723 $ 3,789 $ 3,377 Gross margin 59.6 % 52.9 % 58.6 % 49.8 % Adjusted gross margin percentage (Non-GAAP) 70.7 % 62.7 % 68.4 % 59.3 % ELUTIA INC. EBITDA AND ADJUSTED EBITDA RECONCILIATIONS (Unaudited, in thousands) Three months ended June 30, Six months ended June 30, 2026 2025 2026 2025 Net loss $ (7,646 ) $ (9,610 ) $ (15,115 ) $ (13,543 ) Interest income expense, net(1) (35 ) (491 ) (143 ) (307 ) Provision for income taxes 8 8 78 16 Depreciation and amortization 348 312 679 598 Earnings before interest, taxes, depreciation and amortization ("EBITDA") (Non-GAAP) (7,325 ) (9,781 ) (14,501 ) (13,236 ) Loss (income) from discontinued operations(2) — 2,519 (425 ) 4,565 Stock-based compensation 905 1,028 1,836 2,116 Litigation costs, net(3) 2,057 4,004 2,663 6,576 (Gain) loss on revaluation of warrant liability(4) (226 ) (2,233 ) 1,429 (7,420 ) Warrant issuance expenses — — — 105 Loss on revaluation of revenue interest obligation(5) — 1,442 — 1,442 Adjusted EBITDA (Non-GAAP) $ (4,589 ) $ (3,021 ) $ (8,998 ) $ (5,852 ) (1) Represents interest expense recorded on all outstanding long-term debt as well as the revenue interest obligation. (2) Represents the financial results of the BioEnvelope business sold to Boston Scientific Corporation on October 1, 2025. (3) Represents litigation costs consisting primarily of legal fees and the estimated and actual costs to resolve the outstanding FiberCel and VBM litigation cases offset by the amounts recovered and recoverable under insurance, indemnity and contribution agreements for such costs. (4) Represents the non-cash revaluation of Common Warrants and Prefunded Warrants issued in connection with a private offering in September 2023 and registered direct offerings in June 2024 and February 2025. (5) Represents the non-cash revaluation of the revenue interest obligation. At each reporting period, the value of the revenue interest obligation is re-measured based on current estimates of future payments, with changes to be recorded in the consolidated statements of operations using the catch-up method.

Careers Contact Us Healthcare Professionals Parsippany, NJ – June 8, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the Northern District of Illinois that the patents covering its product MINOCIN® for Injection are valid and infringed by the product developed by Nexus Pharmaceuticals, Inc. Following a four-day bench trial in 2023, the district court found in favor of CorMedix’s wholly owned subsidiary Melinta Therapeutics on all patent infringement and validity issues. The Federal Circuit’s decision on Friday upheld the district court’s findings that Nexus’ proposed generic minocycline product infringes the MINOCIN® patents and rejected Nexus’ invalidity challenge. The Federal Circuit also affirmed the district court’s permanent injunction barring Nexus from marketing its generic product prior to patent expiration. The patents-at-issue are FDA Orange Book listed and protect the company’s innovative reformulation of intravenous minocycline, marketed as MINOCIN® for Injection. MINOCIN® is a tetracycline derived antibiotic used primarily in hospital and acute care settings for patients with a variety of serious and drug-resistant infections. “We are pleased that the Federal Circuit has affirmed the district court’s thorough and well-reasoned decision,” said Joseph Todisco, CorMedix Chairman and CEO. “This ruling validates the strength of the MINOCIN® intellectual property portfolio and recognizes the innovative work that led to important improvements in intravenous minocycline therapy for patients. The decision reinforces the importance of protecting pharmaceutical innovation and the substantial investments required to develop improved therapies. We will continue to protect and defend CorMedix’s intellectual property.” About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as amended (the “Exchange Act”), that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements including, but not limited to statements regarding financial and business guidance; sales, revenue and operating expense estimates; synergy estimates and timing; accretion estimates; and Adjusted EBITDA estimates. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. In addition, pro forma financial information does not necessarily reflect the actual results that we would have achieved had the pro forma transaction been consummated as of the date indicated nor does it reflect the potential future results of the combined company. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Investor Contact: Dan Ferry Managing Director LifeSci Advisors daniel@lifesciadvisors.com (617) 430-7576